vNOTES中的抗菌预防策略:无共识,但我们知道什么?
本文为综述,检索PubMed/MEDLINE和Cochrane Library,纳入83项研究共11,963例患者、9,173例vNOTES病例,评估vNOTES术后感染率、预防性抗菌药物使用及推荐。结果显示vNOTES子宫切除(4,483例)感染率低:盆腔脓肿/感染性血肿0.13%、阴道残端感染0.4%、尿路感染1.6%、术后发热0.77%、手术部位感染0.27%、脓毒症0.02%;非vNOTES子宫切除(2,152例)发热3.2%、阴道残端感染0.73%。附件手术中vNOTES(2,614例)盆腔炎0.4%、尿路感染0.18%,腹腔镜(519例)仅报告发热1.77%。预防性抗菌药物方面,33%研究未报告术前方案,30%使用第一代头孢菌素,19%使用头孢菌素联合甲硝唑或克林霉素,17%报告术后抗生素。结论认为vNOTES抗菌预防无共识,当前证据提示vNOTES不增加感染风险,但前瞻性研究数据有限。
要点
- vNOTES子宫切除(4,483例)感染率低:盆腔脓肿/感染性血肿0.13%、阴道残端感染0.4%、尿路感染1.6%、脓毒症0.02%。
- 非vNOTES子宫切除(2,152例)发热3.2%、阴道残端感染0.73%,高于vNOTES子宫切除的发热0.77%、阴道残端感染0.4%。
- 附件手术中vNOTES(2,614例)盆腔炎0.4%、尿路感染0.18%;腹腔镜(519例)仅报告发热1.77%。
- 预防性抗菌药物无共识:33%研究未报告术前方案,30%用第一代头孢菌素,19%用头孢菌素联合甲硝唑或克林霉素,17%报告术后抗生素。
- 当前证据提示vNOTES不增加感染风险,但前瞻性研究数据有限。
适用人群与场景
- 接受vNOTES妇科手术的患者,包括vNOTES子宫切除、附件手术及其他vNOTES手术(如盆底手术、子宫肌瘤剔除术)。
处置流程与药物剂量
- 预防性抗菌药物无统一方案;文献中常用第一代头孢菌素,或头孢菌素联合甲硝唑或克林霉素。
- 33%的研究未报告任何术前抗菌药物方案,17%的研究报告了术后抗生素使用。
研究设计与关键结果
- 综述纳入83项研究,共11,963例患者、9,173例vNOTES病例。
- vNOTES子宫切除(4,483例)感染率:盆腔脓肿/感染性血肿0.13%、阴道残端感染0.4%、尿路感染1.6%、术后发热0.77%、手术部位感染0.27%、脓毒症0.02%。
- 非vNOTES子宫切除(2,152例)感染率:发热3.2%、阴道残端感染0.73%。
- 附件手术:vNOTES(2,614例)盆腔炎0.4%、尿路感染0.18%;腹腔镜(519例)仅报告发热1.77%。
- 其他vNOTES手术(619例):尿路感染2.3%、盆腔脓肿0.69%。
- 预防性抗菌药物:33%研究未报告术前方案,30%使用第一代头孢菌素,19%使用头孢菌素联合甲硝唑或克林霉素,17%报告术后抗生素。
证据类型、等级与局限
- 证据类型:综述。
- 局限:前瞻性研究数据有限。
对床旁实践的改变
- 当前证据提示vNOTES不增加感染风险,但抗菌预防方案无共识,常用第一代头孢菌素或头孢菌素联合甲硝唑或克林霉素。
指南或共识出处
- Eur J Obstet Gynecol Reprod Biol
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Vaginal natural orifice transluminal endoscopic surgery (vNOTES) combines vaginal and laparoscopic techniques and is increasingly used in gynecologic surgery. Given the lack of standardized guidelines for antibiotic prophylaxis, this review aims to evaluate infection rates, current prophylactic practices, and recommendations.
METHOD: A literature search was conducted in PubMed/MEDLINE and the Cochrane Library using Medical Subject Headings (MeSH) and keywords such as "v-NOTES," "infection," "prophylaxis," and "antibiotics". Studies were grouped into vNOTES hysterectomy, adnexal surgery, and other vNOTES procedures (e.g., pelvic floor surgery, myomectomy). Extracted data included procedure types, indications, operative time, antimicrobial use, follow-up, and postoperative infections.
RESULTS: A total of 83 studies involving 11,963 patients and 9,173 vNOTES cases were analyzed. Among 4,483 vNOTES hysterectomies, infection rates were low: pelvic abscess/infected hematoma (0.13 %), vaginal cuff infection (0.4 %), urinary tract infection (UTI) (1.6 %), postoperative fever (0.77 %), surgical site infection (0.27 %), and sepsis (0.02 %). In 2,152 non-vNOTES hysterectomies, higher rates were noted, including fever (3.2 %) and vaginal cuff infection (0.73 %). In adnexal surgeries (2,614 vNOTES vs. 519 laparoscopy), vNOTES had low infection rates (e.g., pelvic inflammatory disease (PID) 0.4 %, UTI 0.18 %), while laparoscopy reported only fever (1.77 %). Among 619 other vNOTES procedures, UTIs (2.3 %) and pelvic abscess (0.69 %) occurred. Regarding antimicrobial prophylaxis, 33 % of studies did not report any preoperative regimens, 30 % used first-generation cephalosporins, and 19 % used a cephalosporin plus metronidazole or clindamycin. Postoperative antibiotics were reported in 17 %.
CONCLUSION: No consensus exists for antibiotic prophylaxis in vNOTES. First-generation cephalosporins or a cephalosporin plus metronidazole or clindamycin were generally used. Although data from prospective studies are limited, current evidence suggests that vNOTES does not have an increased infection risk.
参考来源
- Ozcivit Erkan IB, Telek SB, Sacinti KG, et al. Antimicrobial prophylactic strategies in vNOTES: No consensus, but what do we know? Eur J Obstet Gynecol Reprod Biol. 2025. PMID: 40912165. doi:10.1016/j.ejogrb.2025.114687
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。